Aleksandra Izabela Masłowska

Aleksandra Izabela Masłowska

Auto-generated profile, based on publicly available information

Aleksandra Izabela Masłowska

Military Institute of Medicine – National Research Institute, Szaserów 128, 04-141 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
MBMarcin Braun
Marcin Braun
JSJulia Sołek
Julia Sołek
GSGrzegorz Stępień
Grzegorz Stępień
AMAleksandra Izabela Masłowska
Aleksandra Izabela Masłowska
MKMateusz Kamecki
Mateusz Kamecki
RKRadzisław Kordek
Radzisław Kordek
Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Accurate differentiation between adenocarcinoma (ADC) and squamous cell carcinoma (SCC) is critical for informing personalized therapies. Thyroid transcription factor-1 (TTF-1) and p40 are traditionally regarded as mutually exclusive markers of ADC and SCC, respectively. However, a subset of tumors exhibits co-expression of TTF-1 and p40, presenting diagnostic challenges and suggesting underlying biological distinctiveness. This study aimed to characterize the clinicopathological, molecular, and immunohistochemical features of NSCLCs co-expressing TTF-1 and p40, in order to clarify their biological and clinical significance. Methods: A retrospective analysis was performed on NSCLC cases diagnosed at the Central Clinical Hospital of the Medical University of Łódź between May 2021 and November 2022. Clinicopathological and survival data were collected. Tumors co-expressing TTF-1 and p40 underwent immunohistochemical evaluation and RNA/DNA-based next-generation sequencing (NGS). Results: Of 94 NSCLC cases analyzed, 18 (19.1%) demonstrated co-expression of TTF-1 and p40. These tumors were significantly more likely to exhibit solid growth patterns compared to control cases (P=0.03), but no significant difference in overall survival (OS) was observed (P=0.46). Among 17 samples subjected to NGS, genetic alterations were identified in 15 (88.2%) cases, with TP53 mutations in 11 (64.7%), KRAS in 4 (23.5%), FGFR1–3 in 4 (23.5%) and EGFR in 2 (11.8%) cases. Immunohistochemical analysis of 18 tumors revealed strong p63 and p53 expression in 11 (61.1%) and 13 (72.2%) cases, respectively. FGFR4 protein was abundantly expressed in 15 cases (83.3%, H-score >150), while elevated H-scores for FGFR1, FGFR2, and FGFR3 were observed in 10 (55.6%), 7 (38.9%), and 2 (11.1%) cases, respectively. Conclusions: NSCLCs co-expressing TTF-1 and p40 appear to represent a biologically distinct and poorly differentiated subgroup, frequently associated with TP53 mutations and FGFR pathway alterations. These tumors may arise from basal reserve cells and undergo TP53-driven reprogramming, diverging from the classical pathways of ADC and SCC. Accordingly, they may be more appropriately classified as NSCLC, not otherwise specified (NOS), rather than strictly as ADC or SCC. Given their molecular complexity, broader genomic profiling may be warranted in these cases, even though current guidelines do not recommend routine molecular testing for SCC.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JLJulia Lenkiewicz
Julia Lenkiewicz
MTMarcin Trzciński
Marcin Trzciński
OLOliwia Lenkiewicz
Oliwia Lenkiewicz
AKAgata Kotłowska
Agata Kotłowska
ZCZuzanna Chmielewska
Zuzanna Chmielewska
GLGabriela Luba
Gabriela Luba
Chronic myeloid leukemia is defined by the presence of the BCR::ABL1 fusion, which plays a central role in disease pathogenesis, diagnosis, treatment selection, and molecular monitoring. This narrative review aimed to summarize the current clinical significance of BCR::ABL1, with particular emphasis on diagnostic methods, assessment of response to tyrosine kinase inhibitors, mechanisms of resistance, and treatment-free remission. A literature search was conducted using PubMed and Google Scholar, focusing primarily on English-language guidelines, review articles, and clinically relevant studies published between 2015 and 2025, while also including earlier landmark publications. The review shows that cytogenetic analysis, fluorescence in situ hybridization, and reverse-transcription polymerase chain reaction provide complementary diagnostic information. Serial RT-qPCR measurement of BCR::ABL1 on the International Scale remains the standard method for assessing the depth and kinetics of molecular response. Interpretation should consider previous results, treatment adherence, dose modifications, assay variability, and the overall clinical context. Detection of kinase-domain mutations, particularly T315I, may explain treatment resistance and guide subsequent TKI selection. Targeted next-generation sequencing and digital PCR may improve the detection of resistant subclones and low-level residual disease, but their findings should not be used as isolated treatment criteria. Overall, accurate and standardized BCR::ABL1 monitoring remains essential for individualized CML management, while further research is needed to validate additional prognostic markers and improve prediction of treatment-free remission.

2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
OLOliwia Lenkiewicz
Oliwia Lenkiewicz
JLJulia Lenkiewicz
Julia Lenkiewicz
ZCZuzanna Chmielewska
Zuzanna Chmielewska
MTMarcin Trzciński
Marcin Trzciński
AKAgata Kotłowska
Agata Kotłowska
GLGabriela Luba
Gabriela Luba
Background: Plasma phosphorylated tau at threonine 217 (p-tau217) has emerged as a promising minimally invasive biomarker for the biological detection of Alzheimer’s disease. This review aimed to evaluate the analytical platforms used for plasma p-tau217 measurement, their diagnostic performance, and the principal challenges associated with its implementation in clinical practice. Methods: A structured narrative review of publications issued between 2019 and 2026 was conducted using PubMed/MEDLINE, Scopus, and Web of Science, with Google Scholar and reference-list screening used as supplementary sources. Studies evaluating plasma p-tau217 assays, analytical validation, diagnostic accuracy, comparison with positron emission tomography or cerebrospinal fluid biomarkers, and clinical implementation were included. Owing to substantial methodological and analytical heterogeneity, findings were synthesised narratively. Results: Plasma p-tau217 showed high diagnostic performance for identifying amyloid and tau pathology and generally outperformed other phosphorylated tau isoforms. Mass-spectrometry-based measurement, particularly percentage p-tau217, demonstrated the highest analytical selectivity and diagnostic accuracy. However, fully automated immunoassays showed greater potential for routine laboratory use because of their higher throughput and reduced technical complexity. Diagnostic performance varied according to the assay, cut-off values, clinical setting, disease prevalence, and patient characteristics. A two-cut-off strategy improved classification while retaining an intermediate group requiring confirmatory testing. Conclusions: Plasma p-tau217 may substantially improve access to biological Alzheimer’s disease diagnostics, but it should not be interpreted as a stand-alone test. Clinical implementation requires assay-specific validation, standardization, external quality control, and integration with clinical assessment and confirmatory diagnostic methods.

22 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AMAleksandra Izabela Masłowska
Aleksandra Izabela Masłowska
WNWiktoria Napiórkowska
Wiktoria Napiórkowska
OLOliwia Lenkiewicz
Oliwia Lenkiewicz
AKAgata Kotłowska
Agata Kotłowska
JLJulia Lenkiewicz
Julia Lenkiewicz
MTMarcin Trzciński
Marcin Trzciński
Postoperative ileus (POI) is a multifactorial condition causing the transient cessation of bowel motility, which significantly increases patient morbidity and healthcare costs. This narrative review synthesizes current clinical evidence evaluating the efficacy, safety, and underlying mechanisms of early postoperative coffee administration in mitigating POI. A structured literature search of PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, and Scopus was conducted, focusing on randomized controlled trials, systematic reviews, and meta-analyses that assessed early coffee consumption against standard care in human surgical cohorts. Clinical data consistently demonstrate that coffee significantly accelerates gastrointestinal recovery across colorectal, gynecological, general abdominal, and obstetric surgeries. The intervention effectively reduces the time to first flatus, first defecation, and the tolerance of solid food. These prokinetic benefits are driven by cephalic-vagal reflex stimulation, gastrointestinal hormone secretion, and intrinsic anti-inflammatory properties, with decaffeinated formulations showing comparable efficacy to caffeinated ones. Furthermore, coffee demonstrates a favorable safety profile without elevating overall postoperative complication rates, including anastomotic leakage, and enhances patient compliance. Ultimately, postoperative coffee consumption is a universally accessible, safe, and low-cost dietary intervention that expedites bowel recovery and decreases hospital length of stay. Its routine integration into standardized Enhanced Recovery After Surgery pathways offers a highly pragmatic strategy for managing POI.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AKAgata Kotłowska
Agata Kotłowska
JLJulia Lenkiewicz
Julia Lenkiewicz
WNWiktoria Napiórkowska
Wiktoria Napiórkowska
MTMarcin Trzciński
Marcin Trzciński
OLOliwia Lenkiewicz
Oliwia Lenkiewicz
DGDominika Galińska
Dominika Galińska
Objectives: Dietary supplements and herbal products are widely used by patients undergoing anticancer treatment, and a considerable proportion of this use is never mentioned to their physician. This review summarises current evidence on the prevalence of such use, the pharmacological basis of interactions with anticancer agents, and the factors underlying non-disclosure on the part of both patients and clinicians. Methods: PubMed/MEDLINE and Google Scholar were searched for publications from January 2011, and July 2026, using combinations of terms relating to dietary supplements, herbal medicine, oncological treatment, herb–drug interactions and physician–patient communication. Priority was given to systematic reviews, meta-analyses and studies conducted in populations receiving anticancer treatment. Key findings: Reported prevalence varies widely between studies, depending on which products are counted and on the populations examined. Interactions arise principally through effects on drug metabolism and transport. Patients most often cite the absence of any question from the clinician as their reason for not disclosing; clinicians, in turn, describe their own knowledge of these products as insufficient. Training programmes have been developed to address this, but their effectiveness has yet to be established. Conclusions: Interactions between anticancer agents and dietary supplements or herbal products may be clinically relevant, yet often go unrecognised because their use is not disclosed. Non-disclosure is better understood as a feature of the consultation than as a behaviour of the patient. Two forms of intervention follow: strengthening clinicians' competence, and making enquiry about supplement use routine and free of judgement.

22 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
WNWiktoria Napiórkowska
Wiktoria Napiórkowska
AMAleksandra Izabela Masłowska
Aleksandra Izabela Masłowska
ZCZuzanna Chmielewska
Zuzanna Chmielewska
OLOliwia Lenkiewicz
Oliwia Lenkiewicz
AKAgata Kotłowska
Agata Kotłowska
MTMarcin Trzciński
Marcin Trzciński
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by progressive joint destruction and immunometabolic complications, notably rheumatoid cachexia. This review article investigates the significance and efficacy of resistance exercise in mitigating myopenia, sarcopenic obesity, and systemic inflammation in RA patients. The objective is to elucidate the underlying molecular mechanotransduction pathways, the role of myokines, and the clinical outcomes of progressive resistance training (PRT). A comprehensive review of the current literature, including recent randomized controlled trials and meta-analyses, was conducted to evaluate clinical and physiological effects. The findings indicate that PRT effectively counteracts muscle atrophy by activating the mTORC1 pathway and exerts potent anti-inflammatory effects via the release of muscle-derived interleukin-6 (IL-6). Furthermore, PRT demonstrates synergistic potential with modern biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). Clinically, properly dosed PRT improves functional capacity, reduces cardiovascular risk, and alleviates patient-reported outcomes such as fatigue and sleep disruption, without exacerbating synovial inflammation or radiographic progression in stable RA. We conclude that structured resistance training is a crucial, evidence-based non-pharmacological therapy for RA — warranting equal consideration alongside standard aerobic exercises — and provide structured dosing guidelines based on the FITT-VP framework.